

PMX 205 Trifluoroacetate (514814-49-4 free base)

Chemical Properties


CAS No. :

Formula: C47H63F3N10O8

Molecular Weight: 953.06

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	PMX 205 Trifluoroacetate is a potent complement antagonist of C5a receptor.
Targets(IC50)	Others
In vitro	PMX205, which is an antagonist, gave more effects towards the cell as compared with the treatment of EP54.
In vivo	oral delivery of a cyclic hexapeptide C5a receptor antagonist (PMX205) for 2-3 mo resulted in substantial reduction of pathological markers such as fibrillar amyloid deposits (49-62%) and activated glia (42-68%) in two mouse models of AD. The reduction in pathology was correlated with improvements in a passive avoidance behavioral task in Tg2576 mice. In 3xTg mice, PMX205 also significantly reduced hyperphosphorylated tau (69%). These data provide the first evidence that inhibition of a proinflammatory receptor-mediated function of the complement cascade (i.e., C5aR) can interfere with neuroinflammation and neurodegeneration in AD rodent models, suggesting a novel therapeutic target for reducing pathology and improving cognitive function in human AD patients[3].

Solubility Information

Solubility	DMSO: 100 mg/mL (104.93 mM),Sonication is recommended. H2O: 0.67 mg/mL (0.7 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.0493 mL	5.2463 mL	10.4925 mL
5 mM	0.2099 mL	1.0493 mL	2.0985 mL
10 mM	0.1049 mL	0.5246 mL	1.0493 mL
50 mM	0.021 mL	0.1049 mL	0.2099 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kosni NN, et al. Expression of complement C5a receptor and the viability of 4T1 tumor cells following agonist-antagonist treatment. *J Cancer Res Ther.* 2016 Apr-Jun;12(2):590-6.

Woodruff TM, et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. *J Immunol.* 2008 Dec 15;181(12):8727-34.

Fonseca MI, et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. *J Immunol.* 2009 Jul 15;183(2):1375-83.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481